Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

by Vandana Singh, Benzinga Editor

May 12, 2021 2:15 PM | 1 min read |

Caladrius Biosciences Inc CLBS has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
Cassava Sciences Inc SAVA has been awarded a new $2.7 million research grant award from the National Institutes of Health.
The grant will be used to fund its upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer's disease.
Price Action: CLBS shares are trading 0.68% lower at $1.45, and SAVA shares are down 2.73% at $38.16 during the market session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care Financing Small Cap General Alzheimer's disease Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.